GlaxoSmithKline to Conduct Whole-Genome Association Studies Using Affymetrix Technology
News Oct 06, 2005
Affymetrix Inc. has announced that GlaxoSmithKline (GSK) has selected the Affymetrix GeneChip® Human Mapping 500K Array Set to find the genetic variations associated with diseases.
Under the agreement, GSK will use the arrays to perform whole-genome association studies across tens of thousands of samples.
The Affymetrix GeneChip 500K is designed to enable researchers to examine the entire genome in more detail.
Affymetrix claims that, with the array set, scientists can perform an entire association study - from conducting an initial high-resolution scan of the entire genome to identifying the specific SNPs of interest - all on one platform for less than a quarter of a cent per SNP.
The 500K is built on the same industry standard platform as its predecessors, the 10K and 100K, which have been validated in 50 publications.
"This agreement demonstrates the power of genetics in the drug discovery and development process," said Greg Yap, vice president of DNA Products at Affymetrix.
"The GeneChip Human Mapping 500K Array Set enables researchers to perform highly detailed whole-genome association studies for the first time."
"We anticipate that a better understanding of human genetic variations will dramatically accelerate research and, ultimately, help bring more effective tests and therapies to market faster."
Genetic Diversity Helps Protect Against DiseaseNews
Why do populations have genetic diversity when 'Survival of the Fittest' suggests that only one gene pool should thrive? It's a question that is hard to answer experimentally. A new study looking at evolutionary change in real time in tiny fungal parasites may provide a solution.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE